-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $762.256M Est

Benzinga·11/03/2026 21:09:33
Diffusion vocale
Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $762.256 million estimate.